Salivary evaluation in radioactive I¹³¹ treated patients with thyroid carcinoma

radioiodine treatment (I¹³¹) used to treat thyroid carcinomas produces side effects (sialadenitis, xerostomia, dysphagia and caries susceptibility) reflecting in a poor patient quality of life. This study aimed to evaluate the effect of I¹³¹ on salivary function and possible oral impairment.

Thirty-seven patients undergoing I¹³¹ were submitted to oral examination, answer questions regarding xerostomia/hyposalivation and collect saliva at three moments (M1: 30-45 days before I¹³¹, M2: 1-2 days after I¹³¹ and M3: 7-10 days after treatment). Saliva was assayed for flow rate and calcium/phosphate concentrations.

significant difference in calcium/phosphate concentration was shown between M1 and M2, with evident decrease at M2. Flow rate reduced right after treatment with 41% of patients returning to previous rate at M3 (no statistical difference). A higher number of patients related xerostomia and difficulty in swallowing food at M2. The results showed that xerostomia/hyposalivation, dysphagia and calcium/phosphate concentration decrease may be considered early radioiodine side effects.